Commentary|Videos|November 16, 2026

Rocbrutinib Plus R-CHOP Yields High Complete Response Rate in Non-GCB DLBCL

Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.

In an interview with CancerNetwork®, at the 2026 European Society for Medical Oncology (ESMO) Congress, Qingqing Cai, MD, PhD, of the department of Medical Oncology at Sun Yat-sen University Cancer Center in Guangzhou, China, discussed early efficacy findings from a phase 1b study (NCT06251180) of rocbrutinib (LP-168), a fourth-generation Bruton tyrosine kinase (BTK) inhibitor, plus R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated non–germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

Among 15 patients who received at least 4 cycles of the combination, the overall response rate was 100%, and 13 patients achieved a complete response, for a complete response rate of 86.7%. The median time to response was 1.25 months, and the median time to complete response was 2.69 months.¹ Cai placed these early, single-arm findings in context with the randomized phase 3 frontMIND trial (NCT04824092), in which adding tafasitamab-cxix (Monjuvi) and lenalidomide (Revlimid) to R-CHOP reduced the risk of disease progression or death by 25% vs R-CHOP alone in patients with previously untreated high-risk DLBCL (HR, 0.75; 95% CI, 0.59-0.96).²

Transcript:

CancerNetwork: What efficacy was shown with the combination, and how might these data be significant in the context of other successful trials in DLBCL, such as frontMIND?

Cai: The early responses were encouraging. Among the 15 patients who received at least 4 cycles of combination treatment, the ORR [overall response rate] reached 100%, and 13 achieved a complete remission, which gives a complete response [CR] rate of 86.7%. Responses were rapid. The median time to response was 1.25 months, and the median time to CR was 2.69 months. In the circulating tumor DNA [ctDNA] analysis after CR, 7 patients were minimal residual disease [MRD] negative, and 1 result was not available.

frontMIND provides randomized phase 3 evidence that adding tafasitamab and lenalidomide to R-CHOP can improve progression-free survival. Our research provides an early signal in non-GCB disease with an oral fourth-generation BTK inhibitor. The next question is whether this response lasts and translates into a benefit in a controlled trial.

References

  1. Cai Q, Xia Y, Hong H, et al. First report of a phase Ib study of rocbrutinib, a fourth-generation Bruton's tyrosine kinase inhibitor, combined with R-CHOP in patients with previously untreated B-cell lymphoma. Presented at: 2026 ESMO Congress; October 23-27, 2026; Madrid, Spain. Abstract 1457O.
  2. Lenz G, Trněný M, Burke JM, et al. frontMIND: phase 3 study of tafasitamab plus lenalidomide and R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma. J Clin Oncol. 2026;44(suppl 17):LBA7000. doi:10.1200/JCO.2026.44.17_suppl.LBA7000

Related to this article